Cargando…
Strategies to facilitate the discovery of novel CNS PET ligands
Positron Emission Tomography (PET), as a non-invasive translatable imaging technology, can be incorporated into various stages of the CNS drug discovery process to provide valuable information for key preclinical and clinical decision-making. Novel CNS PET ligand discovery efforts in the industry se...
Autores principales: | Zhang, Lei, Villalobos, Anabella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5843814/ https://www.ncbi.nlm.nih.gov/pubmed/29564389 http://dx.doi.org/10.1186/s41181-016-0016-2 |
Ejemplares similares
-
The Current Challenges for Drug Discovery in CNS Remyelination
por: Balestri, Sonia, et al.
Publicado: (2021) -
Metallaphotoredox Aryl and Alkyl Radiomethylation for PET Ligand Discovery
por: Pipal, Robert W., et al.
Publicado: (2020) -
PET Radiotracers for CNS-Adrenergic Receptors: Developments and Perspectives
por: Alluri, Santosh Reddy, et al.
Publicado: (2020) -
Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report
por: Suhara, Tetsuya, et al.
Publicado: (2016) -
Laminin-411 Is a Vascular Ligand for MCAM and Facilitates TH17 Cell Entry into the CNS
por: Flanagan, Ken, et al.
Publicado: (2012)